PTC Therapeutics Q2 revenue $187M; net loss narrows to $99M; NDAs submitted

PTC THERAPEUTICS, INC.

2024-Q2 EPS reported -$2.49 revenue$396,822,000

Q2 total revenue $186.7M vs $213.8M YoY; DMD franchise $118M (Translarna $70M, Emflaza $47M).
Net loss $99.2M improved from $198.9M loss; cash $1.09B after $250M Royalty Pharma put option.
Submitted NDA for sepiapterin (PKU) and resubmitted NDA for Translarna (nmDMD) to FDA in July 2024.
Full-year 2024 revenue guidance $700M-$750M; GAAP R&D+SG&A $740M-$835M.
BLA for AADC deficiency gene therapy accepted with priority review; PDUFA date Nov 13, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.